Limba
|
Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPKwith IC50of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Price | 16.359,00 RON (preturile sunt fara TVA) |
---|---|
Description |
Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPKwith IC50of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2. |